GlassScriptPhysician profile
Rahab M Khalil
NPI 1053487363
$1,441.77
in general payments reported to CMS, 2019-2025
20 companies · $359 in 2025
The $359 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156 · 2020: $17.46 · 2021: $193 · 2022: $171 · 2023: $233 · 2024: $312 · 2025: $359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $810 · Education: $93.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $809.71 |
| Education | $93.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $285.34 | 2022-2025 | |
| Abbvie INC. | $253.25 | 2019-2023 | |
| Astellas Pharma US INC | $235.82 | 2023-2025 | Veozah |
| Exeltis, USA INC. | $160.18 | 2021-2025 | Slynd |
| Hologic Sales and Service, LLC | $140.54 | 2020-2025 | Aptima, Thinprep 2000 Processor |
| Coopersurgical, INC. | $50.76 | 2022-2024 | Paragard T 380a, Paragard T 380a |
| Evofem Biosciences, INC. | $43.67 | 2022-2025 | Solosec, Phexx, Phexxi |
| Agile Therapeutics, INC. | $40.73 | 2021 | |
| Organon LLC | $39.21 | 2022-2025 | Jada System |
| Sumitomo Pharma America, INC. | $33.03 | 2023-2024 | Myfembree |
| Roche Diagnostics Corporation | $32.89 | 2019 | |
| Avion Pharmaceuticals | $28.67 | 2019-2021 | |
| Dysis Medical, INC. | $15.24 | 2021 | |
| Vertical Pharmaceuticals, LLC | $14.93 | 2019 | |
| Amag Pharmaceuticals, INC. | $14.54 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $14.41 | 2019 | |
| Allergan, INC. | $13.28 | 2019 | |
| Daiichi Sankyo INC. | $13.20 | 2019 | |
| Lupin INC. | $12.08 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rahab Khalil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.